Biotech Conference Coverage Week 2 Day 2 part 4 - Enanta Pharmaceuticals, Inc.

ENTA (overview): Enanta is a royalty-supported antiviral developer with more than $200 million of cash, runway into 2029 and two potential upside sources: zelicapavir for pediatric and high-risk adult RSV and an oral immunology pipeline. The most immediate catalyst is Q4 2026 Phase 1 data for its oral KIT inhibitor, a target validated by Celldex’s barzolvolimab. Upside depends on meaningful mast-cell effects while managing potential hematologic or pigment toxicities, and on zelicapavir converting virologic activity into replicable clinical benefit.

Read full article (3 min)